Upadacitinib (Rinvoq®) for atopic dermatitis. HTA ID: 21029

Assessment Status Rapid review complete
HTA ID 21029
Drug Upadacitinib
Brand Rinvoq®
Indication For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older, who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 05/07/2021
Rapid review completed 29/07/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib should not be considered for reimbursement at the submitted price.*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations February 2022.